Discussion of Veru Bearish Report Series pt. 2 by White Diamond Research

In this screen-share, Adam Gefvert, the head analyst from White Diamond Reseach goes over the latest part of a series of short reports unveiling the many problems of Veru Pharma. [NASDAQ: VERU]

Full Short Report: https://whitediamondresearch.com/research/part-2-new-red-flags-emerge-from-verus-phase-3-covid-trial-suggesting-an-fda-rejection-is-likely/

Social media
David Capablanca
Twitter: https://twitter.com/reverse_long
Instagram: https://www.instagram.com/reverse_long